A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Exelixis, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 15,359,916 shares of EXEL stock, worth $514 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares
15,359,916
Previous 15,163,066 1.3%
Holding current value
$514 Million
Previous $341 Million 16.99%
% of portfolio
0.63%
Previous 0.6%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$21.96 - $27.6 $4.32 Million - $5.43 Million
196,850 Added 1.3%
15,359,916 $399 Million
Q2 2024

Aug 09, 2024

BUY
$20.34 - $23.73 $1.25 Million - $1.46 Million
61,350 Added 0.41%
15,163,066 $341 Million
Q1 2024

May 13, 2024

SELL
$20.17 - $23.93 $10.4 Million - $12.3 Million
-514,000 Reduced 3.29%
15,101,716 $358 Million
Q4 2023

Feb 13, 2024

BUY
$19.25 - $24.13 $7.68 Million - $9.62 Million
398,800 Added 2.62%
15,615,716 $375 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $10.8 Million - $12.9 Million
569,327 Added 3.89%
15,216,916 $332 Million
Q2 2023

Aug 11, 2023

SELL
$18.17 - $20.48 $11.5 Million - $12.9 Million
-631,800 Reduced 4.13%
14,647,589 $280 Million
Q1 2023

May 12, 2023

BUY
$16.3 - $19.41 $5.19 Million - $6.18 Million
318,300 Added 2.13%
15,279,389 $297 Million
Q4 2022

Feb 13, 2023

SELL
$14.96 - $17.39 $16 Million - $18.6 Million
-1,069,755 Reduced 6.67%
14,961,089 $240 Million
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $27.5 Million - $39 Million
-1,753,093 Reduced 9.86%
16,030,844 $251 Million
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $16.1 Million - $21.3 Million
921,659 Added 5.47%
17,783,937 $370 Million
Q1 2022

May 13, 2022

SELL
$17.03 - $22.67 $4.06 Million - $5.41 Million
-238,500 Reduced 1.39%
16,862,278 $382 Million
Q4 2021

Feb 11, 2022

SELL
$15.84 - $21.88 $7.08 Million - $9.77 Million
-446,723 Reduced 2.55%
17,100,778 $313 Million
Q3 2021

Nov 12, 2021

SELL
$16.3 - $21.14 $8.72 Million - $11.3 Million
-535,000 Reduced 2.96%
17,547,501 $371 Million
Q2 2021

Aug 13, 2021

SELL
$17.95 - $25.56 $9.88 Million - $14.1 Million
-550,300 Reduced 2.95%
18,082,501 $329 Million
Q1 2021

May 13, 2021

SELL
$20.53 - $25.22 $62.6 Million - $76.9 Million
-3,049,850 Reduced 14.07%
18,632,801 $421 Million
Q4 2020

Feb 10, 2021

SELL
$18.39 - $24.8 $18.1 Million - $24.4 Million
-982,959 Reduced 4.34%
21,682,651 $435 Million
Q3 2020

Nov 13, 2020

SELL
$20.67 - $26.94 $7.05 Million - $9.19 Million
-341,300 Reduced 1.48%
22,665,610 $554 Million
Q2 2020

Aug 13, 2020

BUY
$16.46 - $27.42 $48.3 Million - $80.5 Million
2,935,850 Added 14.63%
23,006,910 $546 Million
Q1 2020

May 14, 2020

BUY
$14.46 - $21.8 $30.6 Million - $46.2 Million
2,117,134 Added 11.79%
20,071,060 $346 Million
Q4 2019

Feb 13, 2020

BUY
$15.15 - $18.89 $47 Million - $58.6 Million
3,104,330 Added 20.91%
17,953,926 $316 Million
Q3 2019

Nov 13, 2019

BUY
$17.68 - $22.65 $24.7 Million - $31.6 Million
1,395,123 Added 10.37%
14,849,596 $263 Million
Q2 2019

Aug 12, 2019

BUY
$18.93 - $24.75 $73.6 Million - $96.3 Million
3,889,200 Added 40.66%
13,454,473 $288 Million
Q1 2019

May 14, 2019

BUY
$19.6 - $24.76 $71.5 Million - $90.3 Million
3,645,546 Added 61.58%
9,565,273 $228 Million
Q4 2018

Feb 13, 2019

BUY
$13.65 - $21.8 $80.8 Million - $129 Million
5,919,727 New
5,919,727 $116 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.8B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.